NCT07161999View on ClinicalTrials.gov

Study of COYA 302 for the Treatment of ALS

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

COYA 302

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (8)

19140

NOT_YET_RECRUITING

Temple Neurology, Philadelphia

30322

NOT_YET_RECRUITING

Emory University, Atlanta

33136

NOT_YET_RECRUITING

University Of Miami, Miami

68510

RECRUITING

Neurology Associates, P.C. Somnos Clinical Research, Lincoln

75206

RECRUITING

Texas Neurology, PA, Dallas

77030

NOT_YET_RECRUITING

Houston Methodist Stanley H. Appel Department of Neurology, Houston

94110

NOT_YET_RECRUITING

California Pacific Medical Center, San Francisco

02114

NOT_YET_RECRUITING

Mass General Brigham, Boston

Sponsors

Lead Sponsor

Coya Therapeutics
All Listed Sponsors
lead

Coya Therapeutics

INDUSTRY